Paroxysmal nocturnal hemoglobinuria revealed by hepatic vein thrombosis (Budd-Chiari syndrome) during Infliximab therapy;Thrombose des veines hépatiques au cours d'un traitement par Infliximab (Remicade®) révélant une hémoglobinurie paroxystique nocturne

Gastroenterologie Clinique et Biologique

Volumn 28, Issue 6-7 I, 2004, Pages 596-599

  Sobkeng Goufack, Enam ^a   Mammou, Saloua ^a   Scotto, Béatrice ^a   De Muret, Anne ^a   Maakaroun, Abdallah ^a   Socie, Gérard ^b   Bacq, Yannick ^a  

^a SERVICE DE DERMATOLOGIE   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DANAPAROID; FLUINDIONE; INFLIXIMAB;

ADULT; ANKYLOSING SPONDYLITIS; ANTICOAGULATION; ARTICLE; BUDD CHIARI SYNDROME; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; HUMAN; HUMAN TISSUE; LIVER VEIN THROMBOSIS; MALE; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; THROMBOPHILIA; TREATMENT OUTCOME;

EID: 3142733408     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0399-8320(04)95017-8     Document Type: Article

References (20)

1. Socie G, Mary JY, de Gramont A, Rio B, Leporrier M, Rose C, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet 1996;348: 573-7.
2. Valla D, Dhumeaux D, Babany G, Hillon P, Rueff B, Rochant H, et al. Hepatic vein thrombosis in paroxysmal nocturnal hemoglobinuria. A spectrum from asymptomatic occlusion of hepatic venules to fatal Budd-Chiari syndrome. Gastroenterology 1987;93:569-75.
3. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000:343:1594-602.
4. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JE et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9.
5. Colombel JF, Loftus EV, Jr., Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004;126:19-31.
6. Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 2003;48:2224-33.
7. Richards SJ, Rawstron AC, Hillmen P. Application of flow cytometry to the diagnosis of paroxysmal nocturnal hemoglobinuria. Cytometry 2000;42:223-33.
8. Rosse WE. New insights into paroxysmal nocturnal hemoglobinuria. Curr Opin Hematol 2001;8:61-7.
9. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995;333: 1253-8.
10. Valla DC. The diagnosis and management of the Budd-Chiari syndrome: consensus and controversies. Hepatology 2003;38:793-803.
11. Roche J, Sotto JJ, Michallet M, Faure H, Letoublon C, Bonnet-Eymard J. Syndrome de Budd-Chiari au cours d'une hémoglobinurie nocturne paroxystique. Gastroenterol Clin Biol 1979;3:837-42.
12. Ray JG, Burows RF, Ginsberg JS, Burrows EA. Paroxysmal nocturnal hemoglobinuria and the risk of venous thrombosis: review and recommendations for management of the pregnant and nonpregnant patient. Haemostasis 2000;30:103-17.
13. Hugel B, Socie G, Vu T, Toti F, Gluckman E, Freyssinet JM, et al. Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia. Blood 1999;93:3451-6.
14. Bemba M, Guardiola P, Garderet L, Devergie A, Ribaud P, Esperou H, et al. Bone marrow transplantation for paroxysmal nocturnal haemoglobinuria. Br J Haematol 1999;105:366-8.
15. Clark DA, Butler SA, Braren V, Hartmann RC, Jenkins DE, Jr. The kidneys in paroxysmal nocturnal hemoglobinuria. Blood 1981;57: 83-9.
16. Yee AM, Pochapin MB. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy. Ann Intern Med 2001;135:27-31.
17. Puli SR, Benage DD. Retinal vein thrombosis after infliximab (Remicade) treatment for Crohn's disease. Am J Gastroenterol 2003;98:939-40.
18. Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 2000:119:1148-57.
19. Brousse C. Les inhibiteurs du TNFalpha. Rev Med Interne 2003;24: 123-6.
20. Cambien B, Bergmeier W, Saffaripour S, Mitchell HA, Wagner DD. Antithrombotic activity of TNF-alpha. J Clin Invest 2003;112:1589-96.